SCHEMBL4597591

SCHEMBL4597591

N#CCCOc1ccccc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.53
TDP1 Q9NUW8 2/20 0.53
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 5/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
RECQL P46063 1/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31391953 1.00 L3MBTL1 (0.53) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL11764831 0.86 KDM4E (0.48) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL5539094 0.81 L3MBTL1 (0.53) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL31621296 0.80 KCNN4 (0.48) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL3256218 0.80 KCNN4 (0.48) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL15250195 0.80 L3MBTL1 (0.41) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL1485201 0.77 CYP1A2 (0.56) TDP1ALDH1A1MAPTLMNAHTT
SCHEMBL3727472 0.77 L3MBTL1 (0.50) L3MBTL1TDP1KMT2AMEN1ALDH1A1
SCHEMBL3731507 0.77 ALDH1A1 (0.55) L3MBTL1TDP1KMT2AALDH1A1MAPT
SCHEMBL13684907 0.77 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377434-B2 Methods for preparing substituted chromanone derivatives HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) 2022-07-05 US disclosed
WO-2022016309-A1 METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) 2022-01-27 WO disclosed
US-20220024890-A1 METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) 2022-01-27 US disclosed
EP-1786823-B1 ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BAYER SCHERING PHARMA AG (DE) 2008-01-16 EP disclosed
CN-101087780-A Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs BAYER SCHERING PHARMA AG (DE) 2007-12-12 CN disclosed
CN-101065386-A Alkylidene-tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents SCHERING AG (DE) 2007-10-31 CN disclosed
EP-1786823-A1 ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Bayer Schering Pharma Aktiengesellschaft (DE) 2007-05-23 EP disclosed
US-20060167025-A1 Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs SCHERING AG (DE) 2006-07-27 US disclosed
WO-2006066950-A2 TRICYCLIC AMINOALCOHOLS, METHODS FOR PRODUCING THE SAME AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-06-29 WO disclosed
US-20060084652-A1 Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2006-04-20 US disclosed
WO-2006027236-A1 ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167025-A1 Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs ALDH7A1, NOTUM, GOT2 L3MBTL1 4874/4885TDP1 2506/4885KMT2A 3173/4885
US-20060084652-A1 Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents PTGES, PTGS1, PTGES2 L3MBTL1 4871/4885TDP1 3064/4885KMT2A 4743/4885
US-20220024890-A1 METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES CBR3, CYP2F1, CBR1 L3MBTL1 4174/4885TDP1 2358/4885KMT2A 3543/4885
US-11377434-B2 Methods for preparing substituted chromanone derivatives CYP2E1, CYP2F1, CBR1 L3MBTL1 3937/4885TDP1 1785/4885KMT2A 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.